Ignyta starts phase 1b basket trial of RXDX-105
The Phase 1b portion of the study utilizes a basket design focusing on patients with solid tumors that contain molecular alterations of RET or BRAF. "We are excited
QIAGEN’s Digital Insights bioinformatics division is set to integrate NVIDIA’s accelerated computing and the BioNeMo platform to enhance AI-driven drug discovery.
That’s why researchers at Hennepin County Medical Center (Minneapolis, Minn.) and the University of Minnesota are launching an innovative, comprehensive study in collaboration with Abbott (NYSE: ABT) to